Business
Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine
Majority of physicians indicate improved efficacy is most significant unmet need in the acute treatment of migraine Majority of physicians would be more
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"Majority of physicians indicate improved efficacy is most significant unmet need in the acute treatment of migraine\n Majority of physicians would be more likely to prescribe AXS-07 over current and other emerging treatments if AXS-07 efficacy is confirmed in ongoing MOMENTUM Phase 3 trial MINDSET results confirm rationale for the ongoing MOMENTUM and INTERCEPT Phase 3 trials of AXS-07 Survey physicians treat in aggregate more than 50,000 migraine patients annually NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced results of the “Migraine Treatment Needs and Physician Receptivity” (MINDSET) survey, which demonstrated a significant unmet need for more efficacious acute migraine treatments and a high willingness of physicians to prescribe AXS-07 should it meet the objectives of the ongoing MOMENTUM Phase 3 trial in patients with difficult-to-treat migraines. MINDSET surveyed 106 neurologists and other migraine-treating physicians, who collectively treat more than 50,000 migraine patients annually, to understand physicians’ views of the unmet needs in the acute treatment of migraine and their potential receptivity to AXS-07. AXS-07 (MoSEIC™ meloxicam/rizatriptan) is a novel, oral, investigational medicine with distinct dual mechanisms of action, currently being evaluated in two Phase 3 efficacy trials (MOMENTUM and INTERCEPT) for the acute treatment of migraine. According to the vast majority of physicians (85%), the most significant unmet need in the acute treatment of migraine is efficacy, and the majority of their patients who switch acute migraine treatments (62%) do so because of suboptimal efficacy. Physicians would prescribe AXS-07 to 37% of their patients who experience difficult-to-treat migraine if it demonstrates efficacy over placebo in the ongoing MOMENTUM trial in patients with a history of inadequate response. If AXS-07 demonstrates superior efficacy to rizatriptan as assessed in the MOMENTUM trial, approximately 90% of physicians report they are more likely to prescribe AXS-07 over currently available treatments, and over other emerging therapies, including oral CGRPs, that have not demonstrated superiority to current therapies. More t...